OncoZenge AB

8LY

Company Profile

  • Business description

    OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.

  • Contact

    Gustavslundsvagen 34
    Bromma167 51
    SWE

    E: [email protected]

    https://www.oncozenge.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    1

Stocks News & Analysis

stocks

Shares leap for ASX rare earths provider

We increased our fair value based on higher expected rare earths pricing.
stocks

Strong growth from ASX listed data centre provider

A wall of demand is driving revenue growth.
stocks

Does SpaceX’s sky-high valuation make sense?

SpaceX’s $1.5 trillion valuation looks expensive and risky, but not irrational.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,851.4029.00-0.33%
CAC 408,041.8115.55-0.19%
DAX 4023,640.03328.60-1.37%
Dow JONES (US)47,417.27289.24-0.61%
FTSE 10010,353.7758.47-0.56%
HKSE25,714.07184.69-0.71%
NASDAQ22,716.1319.030.08%
Nikkei 22554,452.96572.41-1.04%
NZX 50 Index13,199.29104.920.80%
S&P 5006,775.805.68-0.08%
S&P/ASX 2008,629.0014.20-0.16%
SSE Composite Index4,129.104.33-0.10%

Market Movers